Lin-Chi Chen

831 total citations
18 papers, 621 citations indexed

About

Lin-Chi Chen is a scholar working on Infectious Diseases, Oncology and Molecular Biology. According to data from OpenAlex, Lin-Chi Chen has authored 18 papers receiving a total of 621 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 10 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Lin-Chi Chen's work include HIV/AIDS drug development and treatment (8 papers), Cancer-related Molecular Pathways (7 papers) and Acute Myeloid Leukemia Research (5 papers). Lin-Chi Chen is often cited by papers focused on HIV/AIDS drug development and treatment (8 papers), Cancer-related Molecular Pathways (7 papers) and Acute Myeloid Leukemia Research (5 papers). Lin-Chi Chen collaborates with scholars based in United States, Canada and United Kingdom. Lin-Chi Chen's co-authors include Arturo Casadevall, Júnia Soares Hamdan, Sarah P. Franzot, Jean Mukherjee, Robert Cherniak, Steven Blotner, Lee M. Krug, Liise‐anne Pirofski, David L. Goldman and Tamara L. Doering and has published in prestigious journals such as The Journal of Experimental Medicine, Blood and Cancer Research.

In The Last Decade

Lin-Chi Chen

18 papers receiving 614 citations

Peers

Lin-Chi Chen
Douglas A. Dedera United States
Xianbo Huang China
Hsin-Yu Chang Taiwan
Cécile Tétaud France
Michal Šmahel Czechia
Nir Dotan United States
Laurene S. Cheung United States
Armelle Goubard France
Mercedes Bermejo Spain
Jennifer Mariner United States
Douglas A. Dedera United States
Lin-Chi Chen
Citations per year, relative to Lin-Chi Chen Lin-Chi Chen (= 1×) peers Douglas A. Dedera

Countries citing papers authored by Lin-Chi Chen

Since Specialization
Citations

This map shows the geographic impact of Lin-Chi Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lin-Chi Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lin-Chi Chen more than expected).

Fields of papers citing papers by Lin-Chi Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lin-Chi Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lin-Chi Chen. The network helps show where Lin-Chi Chen may publish in the future.

Co-authorship network of co-authors of Lin-Chi Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Lin-Chi Chen. A scholar is included among the top collaborators of Lin-Chi Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lin-Chi Chen. Lin-Chi Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Uy, Geoffrey L., Sarit Assouline, Steven Blotner, et al.. (2020). Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia. Investigational New Drugs. 38(5). 1430–1441. 16 indexed citations
2.
3.
Razak, Albiruni R. Abdul, Wilson H. Miller, Geoffrey L. Uy, et al.. (2019). A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors. Investigational New Drugs. 38(4). 1156–1165. 13 indexed citations
4.
Nemunaitis, John, Annie Young, Samuel Ejadi, et al.. (2018). Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 81(3). 529–537. 16 indexed citations
5.
Blotner, Steven, Lin-Chi Chen, Cristiano Ferlini, & Jianguo Zhi. (2018). Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML. Cancer Chemotherapy and Pharmacology. 81(3). 597–607. 12 indexed citations
6.
Yee, Karen, Sarit Assouline, Carolyn D. Britten, et al.. (2018). Abstract A082: A phase I study of the MDM2 antagonist RO6839921, a pegylated intravenous prodrug of idasanutlin, in patients with AML. Molecular Cancer Therapeutics. 17(1_Supplement). A082–A082. 4 indexed citations
7.
8.
9.
Higgins, Brian, Christian Tovar, Aruna Railkar, et al.. (2015). Abstract A156: Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration. Molecular Cancer Therapeutics. 14(12_Supplement_2). A156–A156. 4 indexed citations
10.
Yee, Karen, Giovanni Martinelli, Norbert Vey, et al.. (2014). Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts). Blood. 124(21). 116–116. 58 indexed citations
11.
Rosen, Lee S., Lin-Chi Chen, Jonathan H. Goldman, et al.. (2010). Abstract 2750: ARQ 621, a novel potent and selective inhibitor of Eg5: Preclinical data and early results from a clinical phase 1 study. Cancer Research. 70(8_Supplement). 2750–2750. 6 indexed citations
12.
Krug, Lee M., Daniel T. Milton, Achim A. Jungbluth, et al.. (2007). Targeting Lewis Y (Ley) in Small Cell Lung Cancer with a Humanized Monoclonal Antibody, hu3S193: A Pilot Trial Testing Two Dose Levels. Journal of Thoracic Oncology. 2(10). 947–952. 36 indexed citations
13.
Špíšek, Radek, Anjli Kukreja, Lin-Chi Chen, et al.. (2007). Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy. The Journal of Experimental Medicine. 204(4). 831–840. 152 indexed citations
14.
Chen, Lin-Chi, William D. Travis, & Lee M. Krug. (2006). Pulmonary Neuroendocrine Tumors: What (Little) Do We Know?. Journal of the National Comprehensive Cancer Network. 4(6). 623–630. 29 indexed citations
15.
Chen, Lin-Chi & Arturo Casadevall. (1999). Labeling of Proteins with [35S]Methionine and/or [35S]Cysteine in the Absence of Cells. Analytical Biochemistry. 269(1). 179–188. 5 indexed citations
16.
Chen, Lin-Chi, David L. Goldman, Tamara L. Doering, Liise‐anne Pirofski, & Arturo Casadevall. (1999). Antibody Response to Cryptococcus neoformans Proteins in Rodents and Humans. Infection and Immunity. 67(5). 2218–2224. 57 indexed citations
17.
Chen, Lin-Chi & Arturo Casadevall. (1999). Variants of aCryptococcus neoformansStrain Elicit Different Inflammatory Responses in Mice. Clinical and Diagnostic Laboratory Immunology. 6(2). 266–268. 14 indexed citations
18.
Franzot, Sarah P., Jean Mukherjee, Robert Cherniak, et al.. (1998). Microevolution of a Standard Strain ofCryptococcus neoformansResulting in Differences in Virulence and Other Phenotypes. Infection and Immunity. 66(1). 89–97. 142 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Douglas A. Dedera Breakdown of academic impact, for papers by Xianbo Huang Breakdown of academic impact, for papers by Hsin-Yu Chang Breakdown of academic impact, for papers by Cécile Tétaud Breakdown of academic impact, for papers by Michal Šmahel Breakdown of academic impact, for papers by Nir Dotan Breakdown of academic impact, for papers by Laurene S. Cheung Breakdown of academic impact, for papers by Armelle Goubard Breakdown of academic impact, for papers by Mercedes Bermejo Breakdown of academic impact, for papers by Jennifer Mariner
Rankless by CCL
2026